

SECOND
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/551,094
Filing Date	August 4, 2006
First Named Inventor	Nicholas S. Boddy
Examiner Name	
Attorney Docket No.	0056192-000001

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number-Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Figures Appear
US-				
US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	STATUS							Cited in Spec. / Pg. No(s).
	Country Code ¹ , Number, Kind Code			Translation	Tranlation	Partial Summary	Eng. Lang. Summary	Report	Source Copy	IPER	

Enter Office that issued the document, by the two-letter code.

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Albertoni et al., "On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA)", Eur J Clin Pharmacol., Vol. 44, pp. 579-582, 1993, Springer-Verlag, Germany
	Ahn et al., "Chiral Recognition in Gas-Phase Cyclodextrin: Amino Acid Complexes-Is the Three Point Interaction Still Valid in the Gas Phase?", J Am Soc Mass Spectrom, Vol. 12, pp. 278-287, 2001, Elsevier Science, Inc., US
	Bakthiar et al., "A study of the complexation between dimethyl- β -cyclodextrin and steroid hormones using electrospray ionization mass spectrometry", Rapid Communications in Mass Spectrometry, Vol. 11, pp. 1478-1481, 1997, John Wiley And Sons Ltd, England
	Beutler et al., "The treatment of chronic progressive multiple sclerosis with cladribine", Proc. Natl. Acad. Sci. USA, Medical Sciences, Vol. 93, pp. 1716-1720, 1996, National Academy of Sciences, US
	Cheng et al., "Measurement of chiral complexes of cyclodextrin and amino acids by electrospray ionization time-of-flight mass spectrometry", J. Mass Spectrom, Vol. 36, pp. 834-836, 2001, John Wiley & Sons, Ltd., England
	Choi et al., "FT-Raman and FT-IR Spectra of the Non-steroidal Anti-inflammatory Drug Ketoprofen Included in Cyclodextrins", Analytical Sciences, Vol. 17 Supplement, pp. i785-i788, 2001, The Japan Society for Analytical Chemistry, Japan
	Giordano et al., "Thermal analysis of cyclodextrins and their inclusion compounds", Thermochimica Acta 380, pp. 123-151, 2001, Elsevier Science B.V., The Netherlands
	Hwang et al., "Water Suppression That Works. Excitation Sculpting Using Arbitrary Waveforms and Pulsed Field Gradients", Journal of Magnetic Resonance, Series A, Vol. 112, pp. 275-279, 1995, Academic Press, Inc., US
	Lamcharfi et al., "Electrospray Ionization Mass Spectrometry in Supramolecular Chemistry: Characterization of Non-covalent Cyclodextrin Complexes", Journal of Mass Spectrometry, Vol. 31, pp. 982-986, 1996, John Wiley & Sons, Ltd., England
	Loftsson et al., "Pharmaceutical Applications of Cyclodextrin. 1. Drug Solubilization and Stabilization", Journal of Pharmaceutical Sciences, Vol. 85, No. 10, pp. 1017-1025, 1996, American Pharmaceutical Association and the American Chemical Society, US
	Meier et al., "The Influence of β - and γ -Cyclodextrin Cavity Size on the Association Constant with Decanoate and Octanoate Anions", Journal of Inclusion Phenomena and Macrocyclic Chemistry, Vol. 40, pp. 291-295, 2001, Kluwer Academic Publishers, The Netherlands
	Mura et al., "Interactions of ketoprofen and ibuprofen with β -cyclodextrins in solution and in the solid state", International Journal of Pharmaceutics, Vol. 166, pp. 189-203, 1998, Elsevier Science B.V., The Netherlands

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SECOND
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/551,094
Filing Date	August 4, 2006
First Named Inventor	Nicholas S. Bodor
Examiner Name	
Attorney Docket No.	0056192-000001

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
Nolan et al.	"Preparation of Vesicles and Nanoparticles of Amphiphilic Cyclodextrins Containing Labile Disulfide Bonds", Langmuir, Vol. 19, pp. 4469-4472, 2003, American Chemical Society, US
Ramanathan et al.	"Electrospray Ionization Mass Spectrometric Study of Encapsulation of Amino Acids by Cyclodextrins", J. Am Soc Mass Spectrom, Vol. 6, pp. 866-871, 1995, American Society for Mass Spectrometry, US
Redenti et al.	"Raman and Solid State ¹³ C-NMR Investigation of the Structure of the 1 : 1 Amorphous Piroxicam : β-Cyclodextrin Inclusion Compound", Biospectroscopy, Vol. 5, pp. 243-251, 1999, John Wiley & Sons, Inc., US
Sipe et al.	"Cladribine in treatment of chronic progressive multiple sclerosis", The Lancet, Vol. 344, pp. 9-13, 1994, Lancet Publishing Group, England
Szejtli	"Introduction and General Overview of Cyclodextrin Chemistry", Chem. Rev., Vol. 98, pp. 1743-1753, 1998, American Chemical Society, US
Uekama et al.	"Cyclodextrin Drug Carrier Systems", Chem. Rev., Vol. 98, pp. 2045-2076, 1998, American Chemical Society, US
Uekama et al.	"Peracylated β-Cyclodextrins as Novel Sustained-release Carriers for a Water-soluble Drug, Molsidomine", J. Pharm. Pharmacol., Vol. 46, pp. 714-717, 1994, Pharmaceutical Press, England
Taddei et al.	"Influence of Environment on Piroxicam Polymorphism: Vibrational Spectroscopic Study", Biopolymers (Biospectroscopy), Vol. 62, pp. 68-78, 2001, John Wiley & Sons, Inc., US

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.